Spark Therapeutics, a drug developer spun out of Children’s Hospital of Philadelphia, has been granted breakthrough therapy designation. The US Food and Drug Administration (FDA) granted the designation to the spin-out’s lead drug candidate to prevent blindness.
Called Spk-Rpe65, the drug candidate is still experimental. It is hoped that it could treat inherited retinal dystrophies, a range of conditions affecting the eye ultimately leading to blindness.
The FDA designation signifies expedited development and review for Spark’s drug candidate. It is…
